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ABSTRACT
Glucocorticoid-inducedleucine zipper (GILZ) is a137
amino acid protein,rapidlyinduced bytreatment with
glucocorticoids (GC), characterized by a leucine
zipper(LZ)domain(76–97aminoacids),anN-terminal
domain (1–75 amino acids) and a C-terminal PER
domain (98–137 amino acids) rich in proline and
glutamic acid residues. We have previously shown
that GILZ binds to and inhibits NF-kB activity. In the
present study we used a number of mutants with the
aim of defining the GILZ molecular domains respon-
sible for GILZ/p65NF-kB interaction. Results, obtained
by in vitro and in vivo co-immunoprecipitation (Co-IP)
and by transcriptional activity experiments, indicate
that GILZ homo-dimerization, through the LZ domain,
as well as the C-terminal PER domain, particularly the
121–123 amino acids, are both necessary for GILZ
interaction with NF-kB, inhibition of transcriptional
activity and of IL-2 synthesis.
INTRODUCTION
Glucocorticoids (GC) are involved in the physiological regu-
lation of a variety of biological processes including inﬂam-
mation, immune response, metabolism, cell growth and
development. They are of extraordinary therapeutic value in
a wide-range of pathologies including inﬂammatory and
autoimmune diseases (1–4). In particular, immunosuppressive
and anti-inﬂammatory effects are consequences of GC
complex action on innate and adaptive immunity that reﬂects
GC capacity to inhibit T lymphocyte activation. For these
reasons, GC are used as therapeutic agents in several acute
and chronic inﬂammatory/autoimmune diseases and in
organ transplantation where activation and development of
T-cell mediated immunity plays an important role (2,5–7).
Genomic and non-genomic effects are induced by GC treat-
ment.However,mostoftheeffectsaremediatedbymodulation
of gene transcription, through GC interaction with the gluco-
corticoidreceptor(GR),whichfunctionsasaligand-dependent
transcription factor and regulates gene expression directly, by
bindingtoDNA,orindirectlythroughprotein–to–proteininter-
action withothertranscription factors(8–11).Thus,GC inhibit
Tlymphocyteactivationandproliferation,cytokineproduction
and trans-activation of several transcription factorsinvolvedin
T-cell activation processes, such as AP-1 and NF-kB (11–14).
GC inhibit NF-kB activity through different mechanisms
including augmentation of I-kB expression, competition for
co-activatorproteins,suchasCBP/p300,anddirectassociation
ofGRwith NF-kBsubunits (8,12,14).Ithasalsobeen reported
that treatment with dexamethasone (DEX), a synthetic GC,
down-modulates p65NF-kB trans-activation potential in the
absence of any I-kB up-regulation, thus further suggesting
that GC-mediated NF-kB activity inhibition is a complex
mechanism also characterized by some redundancy (15).
Glucocorticoid-induced leucine zipper (GILZ), a GC-
induced gene, was ﬁrst isolated as a DEX-responsive gene
from a thymus subtraction library (16). Based on protein
motifs, GILZ belongs to the leucine zipper (LZ) family and
shares signiﬁcant homology with other members of the
same family (17). The GILZ gene encodes a 137 amino
acid protein characterized by an LZ domain, present in the
central portion (76–97 amino acids) of the molecule, by an
N-terminal domain (1–75 amino acids) that, contrary to other
family members, does not contain an obvious DNA-binding
sequence (18,19) and by a C-terminal domain (98–137
amino acids), proline (P) and glutamic acid (E) rich (PER)
region, containing eight glutamic acid residues, eight proline
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sequences (20). Similar to other protein families, GILZ LZ
is characterized by a heptad repeat of leucine residues
(21,22). The leucine residues are found in position d of con-
ventional nomenclature for LZ heptad repeats (abcdefg) (23)
and constitute a widely observed structural motif that serves
to promote both homo- and hetero-dimerization (24–26). In
particular, dimerization of LZ proteins occurs via the forma-
tion of a short parallel coiled-coil a-helices (27).
GILZ is present in different cell types including T lympho-
cytes and macrophages (28). Treatment with GC induces a
rapid increase of GILZ expression in T lymphocytes, where
it inhibits anti-CD3-induced IL-2 production, IL-2 receptor
(IL-2R) expression, Fas and FasL up-regulation and cell-
death consequent to CD3-induced activation (11,16,29,30),
thus indicating that GILZ mimics GC-mediated effects in T
lymphocytes. Moreover, GILZ expression is down-regulated
by anti-CD3 stimulation, further suggesting that GILZ
contributes to the control of T-cell activation and develop-
ment (11,29). In macrophages, DEX up-regulates GILZ
(28) and GILZ over-expression, like GC, inhibits production
of inﬂammatory mediators and pro-inﬂammatory chemokines
as well as Toll-like receptor expression (31). Most of these
functions, such as T-cell activation, interleukin and chemo-
kine production, are under control of various transcription
factors including NF-kB.
In our previous studies we have shown that GILZ, when
over-expressed by GC treatment or transfection, both func-
tionally and physically interacts with p65NF-kB and inhibits
NF-kB transcriptional activity in T lymphocytes and in
macrophages (29–32). In particular, we have shown that
GILZ associates with and inhibits NF-kB (p65/p52) tran-
scriptional activity, but not with other LZ, such as Fra-1
(29). Moreover, these effects are independent from I-kB
and in fact GILZ does not affect expression of I-kB and
NF-kB subunits, I-kB phosphorylation and degradation or
I-kB/NF-kB binding. Similarly, I-kB does not interfere
with GILZ/NF-kB interaction (29). In addition, GILZ/NF-kB
co-immunoprecipitation (Co-IP) and inhibition of in vivo
trans-activation activity are also detected in transfected cell
lines defective for the entire NF-kB system, including I-kB,
thus indicating that GILZ interaction with NF-kB (p65/p52)
does not require other Rel- or I-kB-related proteins (29). In
the present paper, we have analyzed GILZ/p65NF-kB inter-
action with the aim to identify the GILZ molecular character-
istics responsible for this interaction. Results indicate that
GILZ homo-dimerization and the PER region are necessary
for in vitro and in vivo GILZ interaction with NF-kB and
for in vivo transcriptional activity inhibition.
MATERIALS AND METHODS
Cell lines and plasmid construction
Human kidney epithelial carcinoma cell line 293T and Cos-1
cells were cultured in DMEM supplemented with 10% FBS
(Invitrogen, San Diego, CA) and antibiotics. Mouse
hybridoma T-cell line 3DO, was maintained in suspension
in RPMI medium supplemented with 10% FBS, 10 mM
HEPES buffer and antibiotics. Eukariotic expression plas-
mids pCR3.1-p65, pCR3.1-GILZ, were constructed as
described previously by cloning into the EcoRI site of
pCR3.1 expression vector (Invitrogen), p65, murine GILZ
open reading frame (ORF) cDNA. pCR3.1-p52 was con-
structed by inserting the p52 cDNA ORF into pCR3.1 expres-
sion vector at the EcoRI and PstI sites. Reporter plasmids
containing tandem repeats of either the murine IgK/HIV-kB
(pBIIXLUC) sites linked upstream to a minimal murine c-fos
promoter and luciferase coding sequences were obtained
from R. Dalla Favera (Columbia University, NY). pEGFP-
N1 vector was purchased from Clontech (Palo Alto, CA).
The plasmids encoding GILZ mutants (LZ1-7, DN-GILZ,
DC-GILZ and PER1-10) were constructed by inserting in
EcoRI-digested pCR3.1 fragments generated by PCR, using
appropriate synthetic oligonucleotides as primers and
pCR3.1-GILZ as template. LZ-GILZ mutant was constructed
by substituting the GILZ LZ domain coding sequence with
the CREB LZ domain. Brieﬂy, the murine CREB LZ coding
sequence was reconstructed using two synthetic oligonu-
cleotides (for: 50-AACTGTTTAGAGAACAGAGTGGCAG-
TGCTTGAAAACCAAAACAAAACATTGATTGAGGAG-
CTAAAAGCACTG-30; rev: 50-TCGACAGTGCTTTTAGC-
TCCTCAATCAATGTTTTGTTTTGGTTTTCAAGCACTG-
CCACTCTGTTCTCTAAACAGTT-30; Invitrogen), annealed
with the following conditions: 90 C 4 min, 85 C 4 min,
80 C 4 min, 75 C 4 min, 70 C 10 min and slowly cooled
down to 10 C. The plasmid pCR3.1-GILZ was digested
with HpaI and SalI to remove the GILZ LZ and the
annealed reaction product was inserted into the digested
pCR3.1-GILZ.
Myc-tagged proteins were generated by insertion of GILZ
or GILZ mutants’ cDNA into BamHI and XbaI sites of
pcDNA3.1/Myc-His vector (Invitrogen). Xpress-tagged
GILZ mutants were cloned into BamHI and XbaI sites of
pcDNA6/His vector (Invitrogen), Xpress-tagged p65 was
obtained by cloning in pcDNA6/His the p65 cDNA at
BamHI and NotI sites. The mammalian expression constructs
containing GILZ or its mutants DC-GILZ, DN-GILZ in
N-terminal glutathione S-transferase (GST)-tagged vector
pEBG (kindly provided by W. Kolch, Cancer Research,
UK) were generated by subcloning into BamHI and NotI
sites of the mammalian expressing vector pEBG.
In vitro binding assay
GILZ was in-frame cloned into the pGEX-4T2 plasmid
(Pharmacia, Uppsala, Sweden) as described previously (16).
GST fusion proteins were expressed in BL21 E.coli and puri-
ﬁed with Glutathione Sepharose 4B beads following the
manufacturer’s instructions. GILZ, GILZ mutant and Fra-1
proteins were in vitro translated with [
35S]methionine by
using the rabbit reticulocyte-coupled in vitro transcription
translation system (TNT Promega, Italy), under the T7 pro-
moter according to the manufacturer’s instruction. In vitro
translated proteins were diluted with the binding buffer
[ﬁnal concentration: 25 mM HEPES (pH 7.5), 10% glycerol,
50 mM NaCl, 0.05% Nonidet P-40 and 1 mM DTT] and pre-
cleared with glutathione beads for 45 min at 4 C. GST or
GST–GILZ fusion protein were bound to glutathione beads.
Protein extracts were then incubated with in vitro translated
proteins for 20 min at 20 C. The beads were subsequently
washed ﬁve times with 0.5 ml of phosphate-buffered saline
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sample buffer and were resolved by SDS–PAGE.
Luciferase assay
Calcium phosphate-mediated transient DNA transfection and
luciferase assays were performed as described (33). 293T
cells were plated at 2 · 10
6/100 mm Petri dish 24 h before
transfection. At 48 h after transfection, cells were harvested
and transcription activation was assayed as luciferase activity.
Different amounts of pCR3.1-GILZ (0.05, 0.5 and 5 mg) or
its mutants, plus effector plasmids pCR3.1-p65 (1.5 mg)
and pCR3.1-p52 (0.5 mg), were co-transfected with
15 mg reporter plasmid (pBIIXLUC) and 3 mg pEGFP-N1.
The pEGFP-N1 plasmid was used to normalize the transfec-
tion efﬁciency of each sample. Cell lysis and luciferase
quantiﬁcation were performed using commercial reagents
(Luciferase Reporter Gene Assay, Roche Diagnostics,
Monza, Italy). The values are expressed as fold-increase
above the level of luciferase activity of cells transfected with
the reporter plasmids. The values marked endogenous control
(EC) represent the values obtained by transfection of the
reporterplasmidsalongwiththecontrolpCR-3.1emptyvector.
Immunoprecipitation (IP)
Myc-tagged GILZ or GILZ mutants, Xpress-tagged GILZ
mutants and Xpress-tagged p65 were co-transfected in differ-
ent combination, as described in the Figures, in COS-1 cells
by using DEAE-dextran as described previously (34). After
48 h of transfection, whole-cell extracts were prepared and
IP was performed in Co-IP buffer [50 mM Tris (pH 7.5),
100 mM NaCl, 0.1% Triton X-100 and 15 mM EGTA]
supplemented with 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF). Antigen–antibody complexes were precipitated
with protein G bound to Sepharose beads (Santa Cruz
Biotechnologies, Santa Cruz, CA). After being washed ﬁve
times in Co-IP buffer, the immunoprecipitates were analyzed
by immunoblotting.
GST-GILZ or its mutants GST-DC-GILZ, GST-DN-GILZ
were separately co-transfected with Xpress-tagged p65 in
293T cells by using calcium phosphate method as reported
previously. At 48 h after transfection, cells were harvested
and incubated in Co-IP buffer with glutathione-agarose
beads ON at 4 C. Then, beads were washed ﬁve times in
Co-IP buffer; bound proteins were recovered by boiling
in SDS sample buffer and were analyzed by SDS–PAGE.
Immunoblot analysis
Extracted or immunoprecipitated proteins and analyzed by
western blot as described previously (35). Primary antibodies
used in these experiments were speciﬁc for Xpress and Myc
epitopes (Invitrogen) or GST (Calbiochem, Darmstadt,
Germany). The antigen–antibody complexes were revealed
by enhanced chemiluminescence according to the manufac-
turer’s instructions (Super-Signal, Pierce, Rockford, IL).
Molecular dynamic simulation analysis
A virtual model of GILZ protein corresponding to the wild-
type was constructed according to the computational protocol
reported previously (36). The 3D models of mutants were
obtained replacing the corresponding residues of proline and
glutamate with residues of alanine according to the amino
acid sequences of PER7-9. The above operations were carried
out using Insight-II (Insight-II, Accelrys, San Diego, CA).
Then, the resulting models were energy reﬁned using 1000
steps of conjugate gradients minimization in order to remove
bad contacts. At this purpose, Charmm22 force ﬁeld was used
(37). Each model was solvated with water molecules using
Solvate v.1.0 and its default settings (Solvate v.1.0 is written
by Helmut Grubmu ¨ller, Theoretical Biophysics Group, Institut
fu ¨r Medizinische Optik, Ludwig-Maximilians-Universita ¨t
Mu ¨nchen, Mu ¨nchen, Germany). No counter-ions were
added. All water molecules within 1.5 s of any protein
atom were then removed. After the construction of the solvent
environment, we obtained four systems of  32000 atoms.
All the models were energy minimized for 5000 steps
using the method of conjugate gradients as implemented in
NAMD v.2.5 (38). During the minimization protocol, the
backbone of the enzyme was kept ﬁxed. The water shell
was then equilibrated for 500 ps at 300 K. The temperature
of 300 K was gradually reached starting from 0 K in the
ﬁrst 10 ps of the simulation. The ﬁnal coordinates and veloci-
ties of the resulting three systems were submitted to a ﬁnal
simulation of 3 ns where constrains on the backbone atoms
were removed. The atomic coordinates of each system were
saved every 10 ps. During the simulations, spherical har-
monic boundary conditions (SBC) were applied. SBC
consists in applying a potential with a constant force of
0.1 kcal/mol * A ˚2 and an exponent of two set to a distance
of radius 45 s centred on the centre of mass of the solute.
A time step of 2 fs was used and the ShakeH algorithm
was applied to all hydrogen atoms. Molecular dynamic
calculations were performed using NAMD v.2.5 and the
Charmm22 force ﬁeld.
Enzyme-linked immunosorbent assay (ELISA) assay
3DO cells were transfected by electroporation (300 V and
960 mF) with 15 mg of linearized pCR3.1 vector (control) or
linearized vector containing GILZ or GILZ mutants cDNA.
At 24 h after transfection, cells where plated into 96-well
plates (4-wells for each transfection), previously coated with
anti-CD3 mAb (PharMingen, San Diego, CA, 1 mg/ml).
Eighteen hours after treatment, the supernatants were
collected and IL-2 production content was evaluated by sand-
wich ELISA. The speciﬁc anti-mouse antibody (Ab) used to
capture and detect IL-2 was purchased from PharMingen,
and the assays were performed following the manufacturer’s
instruction. The sensitivity limit was  3 U/ml for IL-2.
Statistical analysis
Each experiment was performed at least three times. Repre-
sentative experiments are shown. Due to the non normal dis-
tribution of the data, nonparametric tests (Kruskall–Wallis’
ANOVA) were adopted for statistical evaluation.
RESULTS
LZ domain is necessary for GILZ homo-dimerization
It has been previously suggested that GILZ could homo-
dimerize (39). We have previously reported results describing
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computer based homology modeling (36). Based on the 3D
GILZ monomer model, we assembled a functionally active
dimer computer analysis-based model showing that GILZ
homo-dimerizes through the LZ domain (76–98 amino
acids, Figure 1). In fact, it is known that LZ can favor protein
dimerization and it has been shown that speciﬁc rules dictate
dimerization speciﬁcity and stability (40–45). In particular,
the presence of three attractive g–e interactions, isoleucine
at the a position, two asparagines at a position of 3rd and
4th heptad, in addition to leucine in all four d positions,
strongly suggest GILZ could form a stable homo-dimer.
With the aim to analyze the possible requirement of GILZ
homo-dimerization for GILZ interaction with NF-kB, we
prepared a number of GILZ mutants at the LZ domain
(Figure 2A) by amino acid replacement at positions d and a
of the heptad repeats, reported previously to be important for
optimal hydrophobic packing of this region and dimerization
(40–44).
Accordingly, we initially constructed mutants by leucine
substitutions (Figure 2A: mutants LZ1, LZ2, LZ3 and LZ4)
at position d (76, 83, 90, 97 amino acids). GST pull-down
binding assay showed that GST–GILZ fusion protein was
not able to bind in vitro translated LZ4 (all four leucines sub-
stituted at positions 76, 83, 90 and 97), whereas it was able to
bind LZ1 (2 leucines substituted at positions 83 and 90), LZ2
(three leucines substituted at positions 76, 83 and 90) and
LZ3 (three leucines substituted at position 83, 90 and 97)
(Figure 2B, column 3). No binding was detected with GST
alone (Figure 2B, column 2). These results indicate that
GILZ can homo-dimerize and that all four leucines in the
LZ domain are important for dimerization.
We then tested the possible relevance of another highly
conserved residue in LZ domain, such as asparagine (87
amino acids), in the third heptad at position a (Figure 2A),
that it is known to be important for homo-dimerization
speciﬁcity (42–44). As shown in Figure 2, the mutant with
asparagine residue mutated to aspartate (LZ5), did not dimer-
ize (Figure 2B, column 3).
Furthermore, it is known that the coiled-coil is stabilized
by polar amino acids usually present at e and g positions,
adjacent to the hydrophobic interface (Figure 2A) (22,45).
To investigate the contribution of these charged amino
acids for GILZ homo-dimerization we generated two differ-
ent mutants: a mutant where all charged amino acids, except
the four leucines and the asparagine, were substituted with
amino acids having an opposite charge (Figure 2A, LZ6),
and a mutant where all amino acids, except the four leucines
and the asparagine, were substituted with non-polar alanine
residues (Figure 2A, LZ7). Results in Figure 2 show that
LZ6 mutant bound GST-GILZ, whereas LZ7 did not
(Figure 2B, column 3). These results indicate that the
presence of charged amino acids within the LZ domain are
necessary for homo-dimerization and that homo-dimerization
can also occur when amino acids of opposite polarity are
substituted in the molecule. Taken together, these results
suggest that the LZ domain is necessary for GILZ homo-
dimerization. As further speciﬁcity control, GILZ binding
to another LZ protein, such as Fra-1, was tested. As shown
in: Figure 2C, GILZ does not binds Fra-1, thus suggesting
for a certain binding speciﬁcity.
To conﬁrm the results obtained by in vitro GST pull-down
assay shown in Figure 2, we performed Co-IP experiments
using cells co-transfected with GILZ and GILZ mutants.
Cos-1 cells were transfected with expression vector contain-
ing Myc- and Xpress-tagged GILZ. GILZ-Xpress protein was
detected in the immunocomplex formed with anti-Myc anti-
body from cell lysates co-transfected with Myc- and Xpress-
tagged GILZ (Figure 3A, column 2), demonstrating that
GILZ homo-dimerizes in vivo. As a control, GILZ-Xpress
was not immunoprecipitated by anti-Myc Ab in cell trans-
fected with GILZ-Xpress alone (Figure 3A, column 1).
Moreover, the results of Co-IP assay performed with
anti-Myc Ab in Cos-1 cells co-transfected with Myc- and
Figure 1. The sequence of 137 amino acid encoded by GILZ gene (A) is folded into a monomer (B), which is constituted by three domains: the N-terminal
domain (NTD, 1–75 amino acids), the leucine zipper (LZ, 76–97 amino acids) and a C-terminal or PER domain (PER, 98–137 amino acids). Then, GILZ
monomer is assembled into a functionally active dimer (C). The 3D model of the dimeric form of GILZ is obtained using the resolved structure of DIP as
template [see Ref. (35)].
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(column 3), LZ2 (column 4), LZ3 (column 5), LZ6 (column 8)
were able to dimerize in vivo, whereas LZ4 (column 6), LZ5
(column 7) and LZ7 (column 9) did not dimerize.
Together these results indicate that the LZ domain is essen-
tial for in vivo GILZ homo-dimerization.
GILZ homo-dimerization is required for
GILZ/NF-kB interaction and for inhibition of NF-kB
transcriptional activity
We have previously shown that GILZ and NF-kB-subunit
p65 (p65NF-kB) can physically interact in vivo and in vitro
(29) and Co-IP analysis in Cos-1 cells co-transfected with
Xpress-p65 and Myc-GILZ conﬁrm these data (Figure 3B,
column 2). Moreover, we used GILZ mutants to evaluate
the possible relevance of homo-dimerization for interaction
with p65NF-kB. Results indicate that mutants which homo-
dimerize (LZ1, LZ2, LZ3 and LZ6), as shown in Co-IP
experiments (Figure 3A), are able to co-immunoprecipitate
with p65 (Figure 3B, respectively columns 3, 4, 5 and 8).
As a control, Xpress-p65 alone was not immunoprecipitated
by anti-Myc Ab (Figure 3B, column 1). On the contrary,
mutants, such as LZ4, LZ5 and LZ7 that do not dimerize
(Figure 3A) did not co-immunoprecipitate with p65
(Figure 3B, respectively columns 6, 7 and 9). These results
indicate that GILZ homo-dimerization is necessary for inter-
action with p65.
GILZ inhibits NF-kB transcription activity in vivo inde-
pendently from other Rel-related or I-kB-related protein
(29). To investigate the role of GILZ homo-dimerization in
modulation of NF-kB transcription activity, we used 293T
cells co-transfected with an NF-kB luciferase-reporter
vector together with p65 and p52, in the presence or
absence of GILZ or GILZ mutants’ co-expression. Results
in Figure 4 conﬁrmed previous data indicating that GILZ
inhibited NF-kB (p65/p52) transcriptional activity (29).
However, this inhibitory effect was not observed when cells
were co-transfected with LZ4, LZ5 or LZ7 mutants that do
not homo-dimerize (Figure 4A). In contrast, LZ1, LZ2, LZ3
and LZ6 mutants that homo-dimerize, inhibited NF-kB
transcriptional activity (Figure 4A). Together these results
suggest that GILZ homo-dimerization is required for inhibi-
tion of NF-kB transcriptional activity. Moreover, by using a
mutant in which we replaced the GILZ dimerization
domain with CREB LZ domain (LZ-GILZ) we found
that there was no difference between GILZ and LZ-GILZ
inhibition of NF-kB transcriptional activity thus suggesting
that the dimerization and inhibition are structurally separate
(Figure 4B).
Figure 2. GILZ LZ domain is necessary for homo-dimerization in vitro.( A) Amino acid sequence of the LZ region of GILZ protein. LZ heptads are grouped
(abcdefg) to help visualize LZ structure and mutations in this region are represented by red colored letters. Numbers in the bottom show amino acid position of
GILZ protein relative to N-terminal region. (B) The
35S-labeled in vitro transcription/translation product of full-length wild-type GILZ was incubated with GST
(column 2) or GST-GILZ or GST-GILZ mutants (column 3) immobilized on glutathione sepharose beads. The protein bound to the resin was eluted, resolved by
SDS–PAGE, and visualized by autoradiography (right panel). 10% input indicates 0.1 vol of the
35S-labeled product used in the pull-down assay (column 1). The
results are representative of one of three independent experiments. (C) The
35S-labeled in vitro transcription/translation product of full-length wild-type Fra-1
was incubated with GST (column 2) or GST-GILZ (column 3) immobilized on glutathione sepharose beads. The protein bound to the resin was eluted, resolved
by SDS–PAGE, and visualized by autoradiography (right panel). 10% input indicates 0.1 volumes of the
35S-labeled product used in the pull-down assay (column
1). The results are representative of one of three independent experiments.
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for inhibition of NF-kB transcriptional activity and
GILZ/p65NF-kB interaction
To determine whether GILZ homo-dimerization is the only
feature required for inhibition of NF-kB transcriptional
activity, we generated a GILZ truncated protein by elimi-
nating ﬂanking LZ domain N-terminal 1–75 amino acids
(DN-GILZ) or C-terminal 98–137 amino acids (DC-GILZ)
(Figure 5A, left part) and tested them in GST-pull-down
experiments. Results indicate that both DN-GILZ and DC-
GILZ were able to homo-dimerize (Figure 5A, right part,
column 3) thus conﬁrming the role of LZ for dimerization.
We also performed Co-IP in Cos-1 cells transfected with
eukaryotic GST–GILZ fusion proteins and Xpress-p65: inter-
estingly, GST-DN-GILZ (column 3), but not GST-DC-GILZ
(column 2) co-immunoprecipitated with p65NF-kB
(Figure 5B), thus suggesting that C-terminal portion of
GILZ protein is important for binding with p65NF-kB
in vivo. Next, we tested the effect of DN-GILZ and DC-
GILZ truncated mutants on in vivo NF-kB transcriptional
activity. Results show that DN-GILZ inhibited NF-kB
transcriptional activity whereas DC-GILZ did not.
Together, above results indicate that: (i) C-terminal part of
GILZ protein (PER region), although not necessary for homo-
dimerization, is important for interaction with NF-kB and for
inhibition of its transcriptional activity, (ii) GILZ homo-
dimerization occurs in absence of PER region, but is not suf-
ﬁcient for NF-kB transcriptional activity inhibition
(Figure 5C) and (iii) N-terminal part of GILZ is not necessary
for homo-dimerization nor for NF-kB binding and inhibition.
Finally, we tested if both C-terminal domains are critical
for function. To serve that purpose we made a system with
a function dimer but only one C-terminal domain by trans-
fecting equimolar GILZ and DC-GILZ plasmids. Results in
Figure 5C indicated that GILZ plus DC-GILZ-transfected
+  +   +   +   +  + ++
- LZ1 LZ2 LZ3 LZ4 LZ5 LZ6 LZ7
Xpress-GILZ + LZ1 LZ2 LZ3 LZ4 LZ5 LZ6 LZ7
Myc-GILZ - GILZ LZ1 LZ2 LZ3 LZ4 LZ5 LZ6 LZ7
IP: anti-Myc
WB: anti-Xpress
WB anti-Myc
Xpress-p65
Myc-GILZ
IP: anti-Myc
WB: anti-Xpress
WB anti-Myc
GILZ
GILZ
  +
A
B
Figure 3. GILZ co-immunoprecipitates with NF-kB in Cos-1 cells and its
homo-dimerization is necessary for GILZ–NF-kB interaction. (A) Lysates
from Cos-1 cells transfected with 10 mg of vector containing Myc-tagged
GILZ or its mutants (LZ1-7) and 10 mg of Xpress-tagged GILZ or its mutants
(LZ1-7), were used for the IP analysis performed using anti-Myc antibody
(Ab). Xpress-tagged GILZ or its mutants in the immunoprecipitates were
detected by western blotting (WB) using anti-Xpress Ab. WB with anti-Myc
Ab was performed to check Myc-tagged GILZ or its mutant’s expression
levels in transfected cells. (B) GILZ–p65NF-kB interaction was assessed by
co-transfection in Cos-1 cells with 10 mg of vector containing Myc-tagged
GILZ or its mutants (LZ1-7) and 10 mg of Xpress-tagged p65 protein. Xpress-
tagged p65 in the immunoprecipitates were detected by WB using anti-Xpress
Ab. WB with anti-Myc Ab was performed to check Myc-tagged GILZ or its
mutants expression level in transfected cells. Figure 4. (A) Homo-dimerization is important for GILZ inhibition of NF-kB
transcriptional activity. Analysis of NF-kB transcriptional activity was
performed in transiently co-transfected 293 cells. Different amounts of
pCR3.1-GILZ (0.05, 0.5 and 5 mg) or its mutants, plus effector plasmids
pCR3.1-p65 (1.5 mg) and pCR3.1-p52 (0.5 mg), were co-transfected with
15 mg of the reporter vector pBIIXLUC. Each transfection was performed in
triplicate, and SD bars are shown. EC indicates endogenous control. (B) GILZ
LZ domain was substituted with CREB LZ domain (LZ-GILZ, upper panel);
NF-kB transcriptional activity was assessed by co-transfecting different
amounts of pCR3.1-GILZ (0.05, 0.5 and 5 mg) or LZ-GILZ mutant, plus
effector plasmids pCR3.1-p65 (1.5 mg) and pCR3.1-p52 (0.5 mg), together
with 15 mg of the reporter vector pBIIXLUC. Each transfection was
performed in triplicate, and SD bars are shown. EC indicates endogenous
control.
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suggesting that both C-terminal domains are important for
function.
Analysis of PER region domains involved
in GILZ/p65NF-kB interaction
Despite the fact that C-terminal part (98–137 amino acids) of
GILZ does not have obvious homologies to any known func-
tional domain, it shows some interesting features. This
40 amino acid region contains eight prolines (P), eight glu-
tamic acid (E) residues and ﬁve PxxP sequences where x
denotes any amino acid (Figure 6A, underscored sequences).
Such motives have been previously shown to mediate
protein–to–protein interaction in eukaryotic cells (20).
To identify the PER region domains involved in GILZ/NF-
kB interaction we generated a number of mutants for this
region that are represented in Figure 6A. First we tested trun-
cated mutants, such as PER1 (truncated at 102 amino acid),
PER2 (truncated at 114 amino acid), PER3 (truncated at
120 amino acid) and PER4 (truncated at 127 amino acid).
Results indicate that PER1, PER2 and PER3 did not inhibit
NF-kB transcriptional activity (Figure 6B). On the contrary,
PER4 inhibited NF-kB activity at the same level as the entire
wild-type GILZ (Figure 6B) suggesting that amino acids
between 120 and 127 are important. Moreover, substitution
of 121–127 amino acids with alanines, completely abrogates
GILZ inhibitory effect (PER5, Figure 6B), suggesting that
this domain is important for GILZ–NF-kB interaction. The
PER region comprising 120–127 amino acids was further
analyzed by mutating PxxP domains. PER6 (120–123
amino acids) and PER5 (121–127 amino acids) completely
lost capability to inhibit NF-kB activity (Figure 6B), whereas
PER7 (with alanine substitution in 123–126 amino acids)
inhibited as wild-type GILZ did, thus indicating that mutation
at the 121–123 within PxxP domain was sufﬁcient to abrogate
the GILZ inhibitory effect on NF-kB transcriptional activity.
Of note, PER8 (115–118 amino acids) also trans-repressed as
GILZ did (Figure 6B), thus indicating that mutants at other
PxxP domains are irrelevant.
Finally, we performed experiments to evaluate the possible
effect of post-translational GILZ modiﬁcations. In particular,
we generated mutants to remove potential phopshorylation
sites at positions 8, 88 and 114. All these mutants did not
lose the ability to dimerize and to trans-repress NF-kB
(data not shown), thus suggesting that the potential phop-
shorylation sites at position 8, 88 and 114 are not important
for GILZ–NF-kB interaction.
Molecular dynamic simulation analysis
Results indicate that the three 121–123 amino acids, within
the PxxP domain of the PER region are important for interac-
tion with NF-kB. Moreover, PER7 with substituted proline
at 123 tends to exclude a role of such residue. To address
the role of proline and glutamic acid residues of PER
domain in GILZ–p65NF-kB interaction, we generated an
additional panel of mutants and tested for ability to dimerize
and inhibit NF-kB transcriptional activity (PER9-11,
Figure 6A). PER9, with all eight glutamic acid residues sub-
stituted with alanine, and PER10, with all 8 proline residues
substituted with alanine retained GILZ ability to trans-repress
Figure 5. Homo-dimerization is necessary but not sufficient for GILZ
inhibition of NF-kB transcriptional activity. (A) Left panel: schematic
representation of GILZ and its deleted mutants. Right panel: The
35S-labeled
in vitro transcription/translation product of full-length wild-type GILZ was
incubated with GST (column 2) or GST-GILZ or GST-GILZ mutants
(column 3) immobilized on glutathione sepharose beads. The protein bound
to the resin were eluted, resolved by SDS–PAGE, and visualized by
autoradiography (right panel). 10% input used in the pull-down assay is
shown in column 1. The results are representative of one of three independent
experiments. (B) Lysates containing Xpress-p65 and GST–GILZ or GST–
DC–GILZ or GST–DN–GILZ fusions proteins were pulled-down by
glutathione Sepharose beads. Presence of fusions proteins was detected by
WB with anti-GST Ab. Xpress-p65 precipitated was detected by WB with
anti-Xpress Ab. (C) Analysis of NF-kB transcriptional activity was
performed on transiently co-transfected 293 cells. Different amounts of
pCR3.1-GILZ (0.05, 0.5 and 5 mg) or its deleted mutants, plus effector
plasmids pCR3.1-p65 (1.5 mg) and pCR3.1-p52 (0.5 m), were co-transfected
with 15 mg of the reporter vector pBIIXLUC. In columns 11–13 (GILZ +D C-
GILZ) equimolar pCR3.1-GILZ (0.025, 0.25 and 2.5 mg) and pCR3.1-DC-
GILZ (0.025, 0.25 and 2.5 mg) plus effector plasmids pCR3.1-p65 (1.5 mg)
and pCR3.1-p52 (0.5 mg), were co-transfected with 15 mg of the reporter
vector pBIIXLUC. Each transfection was performed in triplicate, and SD bars
are shown. EC indicates endogenous control.
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which contains alanine residues in place of all prolines and
all glutamic acids, was not able to inhibit NF-kB transcrip-
tional activity (Figure 6B).
In order to gain insight into the effect that such a double
mutation could produce in the PER region, we carried out
four molecular dynamic simulations with GILZ and its
mutants PER9, PER10 and PER11 to analyze their conforma-
tional space. In particular, we investigated how the proline
and glutamate replacements would affect the conformation
of the PER region. Indeed, the functional activity of protein
domains is often linked to the stabilization/destabilization
of active/inactive conformations. Although the active
conformation of the PER region that binds to and inhibits
NF-kB is not known, some information can be inferred
from the comparative inspection of the conformational pro-
ﬁles displayed by active and inactive GILZ mutants along
molecular dynamic simulations. Thus, we calculated the ﬂuc-
tuation of each residue belonging to the different domains of
GILZ in the four systems. The residue ﬂuctuation is an index
of the stability of a given conformation in proteins and was
calculated averaging the root mean square deviation for
each atom position of the backbone during the whole time
of simulation. In all four systems, the PER region is endowed
with the highest average ﬂuctuation compared to both the LZ
and the N-terminal domain (Table 1). In particular, the
A
B
Figure 6. Role of Pro/Glu rich (PER) region of GILZ in homo-dimerization and NF-kB transcriptional activity. (A) Amino acid sequence of the PER region of
GILZ protein. The C-terminus is denoted with an asterisk. Point mutation is colored in red. PxxP domains are underscored. Numbers in the bottom show amino
acid position of GILZ protein relative to the N-terminus. (B) Different amounts of pCR3.1-GILZ or GILZ mutants (0.05, 0.5 and 5 mg), plus effector plasmids
pCR3.1-p65 (1.5 mg) and pCR3.1-p52 (0.5 mg), were co-transfected with 15 mg of the reporter vector pBIIXLUC. Each transfection was performed in triplicate,
and SD bars are shown. EC indicates endogenous control.
524 Nucleic Acids Research, 2007, Vol. 35, No. 2mutant PER11 displays a higher ﬂuctuation in the PER region
than the wild-type GILZ and PER9-10 mutants (Figure 7A).
This means that the original extended conformation of the
PER region observed in GILZ is destabilized upon proline
and glutamate replacements with alanine residues and
the observed conformational movement is a bending of the
PER region which reduces its overall extension (Figure 7B).
Two events contribute to the driving force of such a move-
ment: (i) the replacement of torsional constrained residues
with alanines which reduces the rigidity of the PER region
and (ii) the substitution of polar charged residues with
hydrophobic ones that decreases the number of hydrogen
bonds in water and, in turn, the stability of the extended
PER chain. The simultaneous presence of both events is
required to promote the above conformational shift. Indeed,
the bending of the PER region is not observed in either
GILZ or PER9-10 mutants, which in these events are respec-
tively absent or partly present.
Since PER9-10 mutants maintain the ability to bind and
inhibit NF-kB, the loss of NF-kB transcriptional inhibition
on part of mutant PER11 is ascribed to the bending conforma-
tion adopted by the terminal PER region that hampers the
interaction with NF-kB. Noteworthy, the bending occurs at
position 116 of the PER region (Figure 7A). Thus, upon the
conformational change, there is a shortening of the extension
of the C-terminal region. We have shown that truncated pro-
teins at positions 102 (PER1), 114 (PER2) and 120 (PER3),
display an impaired ability to inhibit NF-kB. In agreement
with these data, the results of molecular dynamic simulations
conﬁrm that an extended conformation of the region encom-
passing amino acid residues 116–137, comprising the
120–123 domains, is critical to the inhibitor activity of
GILZ on NF-kB.
Mutants able to trans-repress NF-kB also inhibit anti-
CD3-induced IL-2 production
We have previously shown that GILZ inhibits TCR-induced
IL-2 production in T cells (29). To evaluate the role of the
speciﬁc GILZ/NF-kB interaction here described, we tested
the effect of over-expression of GILZ and some of the
above described mutants on IL-2 production in T cells.
Results in Figure 8 show that all the mutants that did not
inhibit NF-kB (LZ5, PER3, PER5 and PER6) did not counter
IL-2 production in anti-CD3 stimulated 3DO T cells, whereas
those that did inhibit NF-kB (PER4 and PER7) were also able
to counter IL-2 production at levels comparable to GILZ
wild-type.
These results indicate that mutations that impair GILZ–
NF-kB interaction and inhibition of NF-kB transcriptional
activity also impair the GILZ capability of inhibiting IL-2
production.
DISCUSSION
GC are used in treatment of many human diseases but induce
a number of different pharmacological effects which can
cause adverse reactions that limit the drug use in patients
(46,47). The deeper study of molecular mechanisms responsi-
ble for GC actions could suggest new therapeutic approaches
aimed at avoiding unwanted adverse effects and increasing
drug treatment efﬁcacy.
Most of GC actions relate to their capability of antagoniz-
ing NF-kB activity through different molecular mechanisms
(8,14,15) including induction of expression of GILZ, a
transcription regulator able to bind to and inhibit NF-kB
activity (29).
The aim of our work was to analyze the molecular features
of GILZ underlying its ability to inhibit NF-kB activity. For
this purpose we have generated a panel of GILZ mutants and
tested their ability to bind and inhibit p65NF-kB. Results
indicate that GILZ homo-dimerization is necessary for NF-
kB inhibition and C-terminal PER region is also important,
in particular the amino acids of the PxxP domain at position
120–123. Moreover, we demonstrated that the dimerization
and inhibition are structurally separate and that both
C-terminal domains are critical for function.
Among several GILZ mutants, we have identiﬁed several
critical features for homo-dimerization. First, it is clear that
the LZ (76–97 amino acids) domain, but not the C-terminal
(98–137 amino acids) or the N-terminal (1–75 amino acids)
domains, is responsible for homo-dimerization. In addition,
characteristics of GILZ LZ are compatible with previously
reﬁned rules that dictate dimerization speciﬁcity and stability
(40–45). For example, the amino acids sequence of the
GILZ LZ it is four heptads long, it forms three attractive
g–e interactions in 1st, 3rd and 4th heptad. Futhermore, it
has isoleucin at a position, 2 asparagine at a position of 3rd
and 4th heptad in addition to leucine in all four d positions.
All these determinants strongly suggest that GILZ would
form a stable homo-dimer and are compatible with our
results. It is noteworthy that LZ6, which contains charged
amino acids of the opposite polarity is still able to homo-
dimerize, indicating that switching to opposite charges does
not affect homo-dimer stability and further suggesting that
it is the presence of positive and negative charges at speciﬁc
positions rather than the amino acid identity that is important
for stabilization of GILZ homo-dimer. Interestingly, all the
mutants that do not homo-dimerize are not able to interact
with p65NF-kB. Moreover, these mutants have lost the abil-
ity to inhibit the transactivating function of NF-kB. These
data clearly indicate that GILZ homo-dimerization is essen-
tial for both binding to NF-kB and functional trans-repression
of NF-kB transcriptional activity.
Previous studies suggest that GILZ is a molecule able to
interact with different proteins (29,36). In particular, we
have shown that GILZ can bind to Raf and that this interac-
tion occurs in reason of a GILZ/Raf ratio of 1:1 (36). In fact,
GILZ mutants unable to homo-dimerize interact with and
inhibit Raf (36). Results here described indicate that GILZ
Table 1. Averages and SDs of backbone fluctuation of residues in different
domains of GILZ
NTD region
RMSD (A ˚)
LZ domain
RMSD (A ˚)
PER region
RMSD (A ˚)
WT 4.51 ± 1.02 5.47 ± 0.88 8.63 ± 2.34
PER9 4.41 ± 0.96 5.62 ± 0.58 8.45 ± 2.43
PER10 4.22 ± 1.14 5.15 ± 0.60 8.30 ± 2.41
PER11 4.28 ± 1.35 5.46 ± 0.84 9.58 ± 3.54
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tion suggesting that GILZ can preferentially interact with
Raf, and inhibit MAPK pathway acting as monomer, while
interacting with and inhibiting NF-kB as a homo-dimer.
Levels of GILZ expression during the time and/or intracellu-
lar distribution could allow the monomer or dimer formation
to gain speciﬁcity for Raf or NF-kB and this hypothesis
warrants further investigation.
To investigate the structural requirements of GILZ–NF-kB
interaction, we have generated and analyzed N- and
C-terminal deletion mutants of GILZ and we have found
that neither C-terminal nor N-terminal parts of the protein
are necessary for homo-dimerization. Nevertheless, mutant
lacking C-terminal region (DC-GILZ), although able to
homo-dimerize was not able to bind p65NF-kB nor to inhibit
NF-kB transcriptional activity suggesting that, in addition to
homo-dimerization, C-terminal part of GILZ is important for
interaction with NF-kB and for its functional trans-
repression. These results exclude a role for N-terminal
domain that has been previously shown to be necessary for
GILZ–Raf interaction (36). Thus while the C-terminal
domain (PER region) is necessary for GILZ–NF-kB interac-
tion, the N-terminal domain is necessary for GILZ–Raf inter-
action (36), further suggesting that, depending on the
monomeric or homo-dimeric conformation and through dif-
ferent domains, GILZ can selectively interact with NF-kB
and/or Raf.
Proline-rich proteins have been implicated in the regulation
of many cell functions (20). Protein–to–protein interactions
are often mediated by the recognition of proline-rich
domains, such as the PxxP motif, by speciﬁc amino acid
sequences including the SH3 and WW modules (20,48,49).
Of note, GILZ C-terminal PER domain contains eight pro-
lines as well as eight glutamic acids within the 40 amino
acids of the C-terminal portion. Moreover, proline residues
are organized in a way to form ﬁve PxxP domains. Although
SH3 and WW domains are not present in NF-kB complex, we
performed experiments to analyze the possible role of the
prolines of the PER region. We have generated mutants of
the GILZ PER region targeting proline and glutamate resi-
dues as well as altering the length of the region. First, we con-
ﬁrmed that alterations in the PER region do not affect the
ability of GILZ to homo-dimerize, since neither truncations
nor proline and/or glutamic acid substitutions affected the
Figure 7. (A) Backbone fluctuation of residues of PER region in the GILZ and PER9-11 mutants. Position 116, where the conformational bending of PER11
mutant starts, is marked with a red line. (B) Comparison of GILZ, PER9, PER10 and PER11 mutant conformations obtained at the end of the simulation. Alanine
residues are shown in CPK style.
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Figure 8. GILZ inhibits anti-CD3 IL-2 production. IL-2 production (U/ml) in
untreated (NT) and anti-CD3 treated (1 mg/ml) for 18 h, empty vector
transfected (pCR3.1) or GILZ or GILZ mutants (LZ5, PER3, PER4, PER5,
PER6 and PER7) transfected 3DO cells as evaluated by ELISA assay. ND:
not detected. Each transfection was performed in triplicate, and SD bars are
shown. *P < 0.05.
526 Nucleic Acids Research, 2007, Vol. 35, No. 2stability of GILZ homo-dimer (data not shown). Results
indicated that GILZ–NF-kB interaction was abrogated by
truncation of PER region at position 120, while it was still
evident with mutant truncated at 127. Moreover, PER6,
with mutated PxxP at 120–123 amino acids lost inhibitory
effect in NF-kB activity, whereas PER7 and PER8, mutated
at other PxxP domains, did maintain inhibitory activity com-
parable to that of GILZ wild-type thus suggesting that the
PxxP at positions 120–123 or part of it, is important for
GILZ/NF-kB interaction. PER5, with substituted amino
acids at positions 121–127, did not inhibit NF-kB activity
thus indicating that 121–123 amino acids, but not the canoni-
cal PxxP motif, are necessary for GILZ–NF-kB interaction.
Consistent with these results, substitution of all prolines
(PER10) did not affect GILZ inhibitory effect on NF-kB tran-
scriptional activity, thus indicating that proline residues are
not necessary for GILZ–NF-kB interaction and further
suggesting that the 121–122 amino acids, within the PxxP
domain, are relevant for this effect.
Similar results were obtained when all glutamic acids were
substituted. As an apparent exception, GILZ inhibitory activ-
ity was lost when all the proline and glutamic acid residues of
PER region were substituted in the same mutant. Noteworthy,
the comparison of GILZ wild-type, PER9, PER10 and PER11
mutant structures, obtained by molecular dynamic simulation
analysis, showed that PER11 mutant adopted a bending con-
formation of the C-terminal region. In particular, the bending
occurred at position 116, before 121 amino acid, and can be
explained by the concomitant presence of two events: the
replacement of all prolines that reduces the conformational
rigidity of the PER region and the insertion of alanines in
place of glutamates that decreases the stability of the
C-terminal region in water. Thus, the overall effect of the
removal of all prolines and glutamates is a conformational
change that leads the PER region to shorten its extension at
position 116. This is in agreement with the lack of activity
observed in C-domain truncated mutants, further suggesting
that PER region length, particularly the 121–123 domains is
important in GILZ–p65NF-kB interaction.
These results are reinforced by investigation with GILZ
and GILZ mutants, on inhibition of IL-2 production. As
reported previously, GILZ is able to inhibit IL-2 production
in anti-CD3-activated 3DO T cells (29). GILZ mutants that
lack inhibitory activity on NF-kB failed to inhibit IL-2 pro-
duction thus suggesting that molecular structural characteris-
tics responsible for inhibition of NF-kB transcriptional
activity have a biological relevance.
In conclusion, we have shown here results aimed at identi-
fying the molecular requirements of GILZ–p65NF-kB inter-
action and evidencing the importance of homo-dimerization
and of the C-terminal PER region, particularly the 121–123
amino acids. Results here reported and previous studies
show that GILZ can bind NF-kB but not other LZ proteins
such as Fra-1, thus suggesting a certain binding speciﬁcity
(29). However, the NF-kB family is composed of a number
of molecules that constitute a complex system of different
homo- and hetero-dimers participating to transcription regu-
lation (50) and future studies will be devoted to analyze
GILZ interaction with other molecules of the NF-kB family.
Identifying the molecular mechanisms of GILZ interaction
with NF-kB family molecules may be an attractive possibility
for future studies aimed at designing new molecules and
therapeutic approaches able to mimic or antagonize GILZ–
NF-kB interaction, thus modulating immune/inﬂammatory
response.
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